Effect of oxidative DNA damage in promoter elements on transcription factor binding

被引:132
作者
Ghosh, R [1 ]
Mitchell, DL [1 ]
机构
[1] Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA
关键词
D O I
10.1093/nar/27.15.3213
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reactive oxygen species produced by endogenous metabolic activity and exposure to a multitude of exogenous agents impact cells in a variety of ways. The DNA base damage 8-oxodeoxyguanosine (8-oxodG) is a prominent indicator of oxidative stress and has been well-characterized as a premutagenic lesion in mammalian cells and putative initiator of the carcinogenic process. Commensurate with the recent interest in epigenetic pathways of cancer causation we investigated how 8-oxodG alters the interaction between cis elements located on gene promoters and sequence-specific DNA binding proteins associated with these promoters. Consensus binding sequences for the transcription factors AP-1, NF-kappa B and Spl were modified site-specifically at guanine residues and electrophoretic mobility shift assays were performed to assess DNA-protein interactions, Our results indicate that whereas a single 8-oxodG was sufficient to inhibit transcription factor binding to AP-1 and Spl sequences it had no effect on binding to NF-kappa B, regardless of its position. We conclude from these data that minor alterations in base composition at a crucial position within some, but not all, promoter elements have the ability to disrupt transcription factor binding, The lack of inhibition by damaged NF-kappa B sequences suggests that DNA-protein contact sites may not be as determinative for stable p50 binding to this promoter as other, as yet undefined, structural parameters.
引用
收藏
页码:3213 / 3218
页数:6
相关论文
共 44 条
[41]  
TROLL W, 1985, ANNU REV PHARMACOL, V25, P509, DOI 10.1146/annurev.pharmtox.25.1.509
[42]   NEU-PROTEIN OVEREXPRESSION IN BREAST-CANCER - ASSOCIATION WITH COMEDO-TYPE DUCTAL CARCINOMA INSITU AND LIMITED PROGNOSTIC VALUE IN STAGE-II BREAST-CANCER [J].
VANDEVIJVER, MJ ;
PETERSE, JL ;
MOOI, WJ ;
WISMAN, P ;
LOMANS, J ;
DALESIO, O ;
NUSSE, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (19) :1239-1245
[43]  
ZAVEL L, 1993, PROG NUCLEIC ACID RE, V44, P67
[44]   Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor [J].
Zhai, XQ ;
Beckmann, H ;
Jantzen, HM ;
Essigmann, JM .
BIOCHEMISTRY, 1998, 37 (46) :16307-16315